

Applicant: Rahal, James  
U.S. Serial No.: 09/935,966  
Amendment  
Page 5 of 6

### **REMARKS**

By this amendment, Applicant has canceled claims 1-4 and 10-15 without disclaimer. Applicant reserves the right to pursue claims 1-4 and 10-15 in one or more continuing applications. Claims 20, 26, 32 and 38 have been amended to include that the interferon can be administered intravenously or subcutaneously or combination thereof (both intravenously and subcutaneously) to the human. New claim 40 includes the claimed dosage regimen of intravenous and subcutaneous administration of interferon. Support for this amendment can be found at, for example, Example 3, and claims 20, 23, 28, 34 and 39 as previously filed. Applicant submits that no new matter is added by this amendment. Entry of the amendment, and reconsideration of the application is respectfully requested.

### **Allowable Subject Matter**

Applicant thanks the Examiner for acknowledging that claims 20-22, 24-28 and 30-39 are allowed.

### **Objections**

The Examiner objects to claims 23, 29 and 35 for improper dependent form. Applicant respectfully disagrees with the Examiner and submits that the claims are in proper dependent form. Nevertheless, to expedite allowance, Applicants have amended Claims 20, 26, 32, and 38 to include that the interferon can be administered intravenously or subcutaneously or combination thereof (intravenously and subcutaneously) to the human. Accordingly, it is respectfully submitted that claims 23, 29 and 35 are in proper dependent form and Applicants request allowance of claims 23, 29 and 35.


Applicant: Rahal, James  
U.S. Serial No.: 09/935,966  
Amendment  
Page 6 of 6

**Conclusion**

Reconsideration and allowance are respectfully solicited.

If the Examiner has any questions regarding the present application, the Examiner is cordially invited to contact Applicant's attorney at the telephone number provided below.

Respectfully submitted,



William D. Schmidt  
Registration No.: 39,492  
Attorney for Applicants

Kalow & Springut LLP  
Telephone: (212) 813-1600  
Facsimile: (212) 813-9600